Merck (MRK), known as MSD outside the U.S., and Canada, Tuesday has inaugurated a new $1 billion, 225,000-square-foot vaccine manufacturing facility at its Durham, North Carolina, site.
This expansion is part of the company's broader $12 billion investment in U.S., manufacturing and R&D since 2018, with an additional $8 billion planned by 2028. The facility integrates advanced technologies, including data analytics, generative AI, 3D printing, and a digital twin for enhanced training and process simulation.
Merck's Executive Vice President, Sanat Chattopadhyay, emphasized the site's role in strengthening domestic production capabilities. Durham plant manager Amanda Taylor highlighted the workforce's dedication in driving this evolution.
MRK is currently trading at $94.9 or 0.35% lower on the NYSE.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.